Company / Operating Cash Flow
Corcept Therapeutics Incorporated Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$142.0M
FY2025
5-year range
$126.7M / $198.3M
FY2021-FY2025
Trend
-28.4%
vs FY2024
Sector context
#46 of 216
Health Care
What the data says
Corcept Therapeutics Incorporated's operating cash flow of $142M is higher than 79% of companies in the Health Care sector (FY2025). Operating Cash Flow has fluctuated over the past 10 years, ranging from -$27M in FY2016 to $198M in FY2024.
Based on SEC 10-K filings.
$142M in FY2025 with a 5-year CAGR of +4.2%. Top quartile in the Health Care sector.
Improved from $127M to $142M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -2.2%
- 5-Year CAGR
- +4.2%
- 10-Year CAGR
- -
Sector benchmark
-78.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +4.2%, indicating consistent growth.
- In FY2025, operating cash flow decreased 28.4% year-over-year.
- Ranks #46 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 3.44 (safe zone, above 2.9 threshold)
- Strong profit margin: 20.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $142.0M | -28.4% |
| FY2024 | $198.3M | +56.5% |
| FY2023 | $126.7M | -16.6% |
| FY2022 | $152.0M | +11.6% |
| FY2021 | $136.1M | +17.7% |
| FY2020 | $115.7M | +89.8% |
| FY2019 | $60.9M | +231.3% |
| FY2018 | $18.4M | -69.8% |
| FY2017 | $60.9M | +322.6% |
| FY2016 | -$27.4M | -974.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026